CORE LABORATORIES N.V. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2020-12-17: Form 8-K; Period of report 2020-12-17; Description 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events; Details 1.01.
- 2020-10-21: Form 8-K; Period of report 2020-10-21; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
- 2020-10-16: Form 8-K; Period of report 2020-10-16; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2020-10-15: Form 8-K; Period of report 2020-10-15; Description 7.01 Regulation FD Disclosure; Details 7.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2020-12-17 | 8-K | 2020-12-17 | 1.01 Entry into a Material Definitive Agreement; 8.01 Other Events | 1.01 Entry into a Material Definitive Agreement. 8.01 On December 17, 2020, the Company issued a press release announcing the establishment of an “at-the-market” equity offering program. | d60191d8k.htm |
| 2020-10-21 | 8-K | 2020-10-21 | 2.02 Results of Operations and Financial Condition | 2.02 On October 21, 2020, Core Laboratories N.V. (the “Company”) issued a press release announcing its financial results for the third quarter of 2020. | clb-8k_20201021.htm |
| 2020-10-16 | 8-K | 2020-10-16 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 On October 16, 2020, Core Laboratories N.V. (the “Company”) and Core Laboratories (U.S.) Interests Holdings, Inc. (the “Issuer”) completed a private placement of $60 million in aggregate principal amount of the Issuer's senior notes with $45 million due 2026 (the “2026 Notes”) at an interest rate of 4.09% and $15 million due 2028 (the “2028 Notes”) at an interest rate of 4.38%. | clb-8k_20201016.htm |
| 2020-10-15 | 8-K | 2020-10-15 | 7.01 Regulation FD Disclosure | 7.01 On October 15, 2020, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on October 26, 2020 and payable November 17, 2020. | clb-8k_20201015.htm |
| 2020-07-22 | 8-K | 2020-07-22 | 2.02 Results of Operations and Financial Condition | 2.02 On July 22, 2020, Core Laboratories N.V. (the “Company”) issued a press release announcing its financial results for the second quarter of 2020. | clb-8k_20200722.htm |
| 2020-07-17 | 8-K | 2020-07-17 | 7.01 Regulation FD Disclosure | 7.01 On July 17, 2020, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on July 27, 2020 and payable August 10, 2020. | clb-8k_20200717.htm |
| 2020-06-23 | 8-K | 2020-06-22 | 1.01 Entry into a Material Definitive Agreement; 7.01 Regulation FD Disclosure; 8.01 Other Events | 1.01 On June 22, 2020, Core Laboratories N.V. (“Core Laboratories”) and Core Laboratories (U.S.) Interests Holdings, Inc. (“Core Laboratories U.S.”) as borrowers, Bank of America, N.A., as Administrative Agent, Swing Line Lender and Letter of Credit Issuer, Wells Fargo Bank, National Association as Syndication Agent, and the other lenders party thereto entered into that certain Amendment No. 1 (the “Amendment”) to the Seventh Amended and Restated Credit Agreement, dated as of June 19, 2018 (as amended, the “Credit Facility”). 7.01 On June 23, 2020, Core Laboratories issued a press release announcing the Amendment and additional cost reduction initiatives. 8.01 Events beyond Core Lab’s control, including a global or domestic health crisis, have resulted and may continue to result in unexpected adverse operating and financial results. | clb-8k_20200622.htm |
| 2020-05-20 | 8-K | 2020-05-20 | 5.07 Submission of Matters to a Vote of Security Holders | 5.07 Core Laboratories N.V. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on May 20, 2020 in Amsterdam, the Netherlands. | clb-8k_20200520.htm |
| 2020-04-28 | 8-K | 2020-04-28 | 7.01 Regulation FD Disclosure | 7.01 On April 28, 2020, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.01 per share of common stock for shareholders of record on May 8, 2020 and payable May 19, 2020. | clb-8k_20200428.htm |
| 2020-04-22 | 8-K | 2020-04-22 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 2.02 On April 22, 2020, Core Laboratories N.V. (the “Company”) issued a press release announcing its financial results for the first quarter of 2020. 5.02 The Company previously announced that, effective as of the conclusion of the 2020 annual shareholders’ meeting on May 20, 2020 (the “2020 Annual Meeting”), David Demshur will retire from his role as Chief Executive Officer and Chairman of the Supervisory Board, but that he would remain employed by the Company to support the transition until his retirement on December 31, 2020. 8.01 The vast and accelerated spread of the COVID-19 virus has resulted in significant disruptions to the global economy. | clb-8k_20200422.htm |
| 2020-03-27 | 8-K | 2020-03-27 | 8.01 Other Events | 8.01 On March 27, 2020, Core Laboratories N.V. (the “Company” or “Core Lab”) issued a press release announcing that the Company has moved the time and location of its 2020 annual meeting of shareholders (the “2020 Annual Meeting”). | clb-8k_20200327.htm |
| 2020-03-16 | 8-K | 2020-03-16 | 7.01 Regulation FD Disclosure | 7.01 On March 16, 2020, Core Laboratories N.V. issued a press release announcing a reduction of the quarterly dividend and expansion of cost reduction initiatives. | clb-8k_20200316.htm |
| 2020-03-05 | 8-K | 2020-03-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On March 1, 2020, Core Laboratories N.V. (the “Company”) entered into an amendment to the March 1, 2019 Employment Agreement, by and between the Company and President and Chief Operating Officer, Mr. Lawrence V. Bruno (the “Amendment”). | clb-8k_20200301.htm |
| 2020-01-29 | 8-K | 2020-01-29 | 2.02 Results of Operations and Financial Condition; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 2.02 On January 29, 2020, Core Laboratories N.V. (the “Company”) issued a press release announcing its financial results for the fourth quarter of 2019 and the year ending December 31, 2019. 5.02 On January 29, 2020, the Company announced that, effective as of the conclusion of the 2020 annual shareholders’ meeting on May 20, 2020 (the “2020 Annual Meeting”), David Demshur has informed the Supervisory Board of Directors of the Company (the “Supervisory Board”) that he will retire from his role as Chief Executive Officer and Chairman of the Supervisory Board. | clb-8k_20200129.htm |
| 2020-01-14 | 8-K | 2020-01-14 | 7.01 Regulation FD Disclosure | 7.01 On January 14, 2020, Core Laboratories N.V. issued a press release announcing a quarterly cash dividend of $0.25 per share of common stock for shareholders of record on January 24, 2020 and payable February 14, 2020. | clb-8k_20200114.htm |